For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Vyndamax and Tafamidis meglumine represents a significant change. These groundbreaking therapies preserve the transthyretin protein, preventing its harmful build-up and lessening the s